The seasonal variation both in immune system and in residual beta cell function may be part of the explanation why the effect of GAD treatment in newly diagnosed T1D has shown best effect in patients diagnosed during early spring 1,2. This evidence concerns the gene GAD1 and type 1 diabetes mellitus.